Tag:
SciClone
Latest Headlines
Latest Headlines
SciClone dumps cancer drug after failed IIb
Foster City, CA-based SciClone Pharmaceuticals ( $SCLN ) has come up empty-handed again after concluding its latest Phase IIb trial for SCV-07 should be shuttered.
SciClone strikes $105M deal to buy China's NovaMed
Lured by the booming Chinese pharmaceuticals market, Foster City, CA-based SciClone Pharmaceuticals ( $SCLN ) has struck a deal to buy Shanghai-based NovaMed Pharmaceuticals for $24.7 million in cash
SciClone shares slide after it dumps failed hep C program
SciClone Pharmaceuticals ( $SCLN ) decided to drop its mid-stage hepatitis C program after the therapy failed to hit its target on reducing the severity of viral infection in a Phase IIb trial. The
SciClone stock surges on Zadaxin news
California-based SciClone Pharmaceuticals' shares shot up as much as 14 percent earlier this week after preliminary study data showed the adjuvant Zadaxin increased immune response when used in
SciClone axes R&D staffers following trial
SciClone Pharmaceuticals' decision earlier this month to suspend its mid-stage pancreatic cancer trial for RP101 will cost the jobs of 17 percent of its U.S. workforce. The developer said that it was
SciClone's hep C drug fails late-stage trial
SciClone Pharmaceuticals' late-stage therapy for hepatitis C failed to hit a primary endpoint in a late-stage trial. The drug, thymalfasin, failed to register a significant response in patients who
